CRISPR Therapeutics (CRSP) Misses Q2 EPS by 100c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($2.40), $1.00 worse than the analyst estimate of ($1.40). Revenue for the quarter came in at $890 thousand versus the consensus estimate of $5.81 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Apple has talked to PrismML about ways it could use its technology - The Information
• MKS Instruments (MKSI) PT Raised to $415 at Mizuho
• duPont REGISTRY Group files confidential IPO registration with SEC